CM
CRSP icon

Caption Management’s CRISPR Therapeutics CRSP Stock Holding History

Caption Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,383
Closed -$131K – 1534
2025
Q1 		$115K Sell
3,383
-22,172
-87% -$940K ﹤0.01% 1341
2024
Q4 		$1.01M Buy
25,555
+24,955
+4,159% +$1.18M 0.01% 914
2024
Q3 		$28.2K Sell
600
-23,539
-98% -$1.19M ﹤0.01% 1190
2024
Q2 		$1.3M Buy
+24,139
New +$1.4M 0.02% 593
2022
Q1 		– Sell
-13,600
Closed -$854K – 1542
2021
Q4 		$1.03M Buy
+13,600
New +$1.19M 0.01% 1038
2018
Q4 		– Sell
-5,000
Closed -$221K – 489
2018
Q3 		$221K Hold
5,000
– – 0.01% 451
2018
Q2 		$294K Buy
+5,000
New +$285K 0.02% 346

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caption Management's CRSP Position: Q2 2025 in Review

Caption Management sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 3,383 shares — an estimated $131K sold.

Caption Management first reported a position in CRSP in Q2 2018 and held it in 7 quarters. The position peaked at $1.3M in Q2 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Caption Management reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 3,383 CRISPR Therapeutics shares in Q2 2025, an estimated $131K.
  • Caption Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 7 quarters.
  • Caption Management's CRISPR Therapeutics position peaked at $1.3M in Q2 2024.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.